Cargando…

Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer

PURPOSE: Triple-negative breast cancer (TNBC) is a subtype associated with poor prognosis and for which there are limited therapeutic options. The purpose of this study was to evaluate the efficacy of ENMD-2076 in p53-mutated TNBC patient-derived xenograft (PDX) models and describe patterns of termi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ionkina, Anastasia A., Tentler, John J., Kim, Jihye, Capasso, Anna, Pitts, Todd M., Ryall, Karen A., Howison, Rebekah R., Kabos, Peter, Sartorius, Carol A., Tan, Aik Choon, Eckhardt, S. Gail, Diamond, Jennifer R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5430301/ https://www.ncbi.nlm.nih.gov/pubmed/28555173 http://dx.doi.org/10.3389/fonc.2017.00094

Ejemplares similares

A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer
por: Diamond, Jennifer R., et al.
Publicado: (2018)

A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS)
por: Veitch, Zachary, et al.
Publicado: (2019)

An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer
por: Ryall, Karen A, et al.
Publicado: (2015)

Selected by gene co-expression network and molecular docking analyses, ENMD-2076 is highly effective in glioblastoma-bearing rats
por: Zhong, Sheng, et al.
Publicado: (2019)

Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer
por: Pitts, Todd M., et al.
Publicado: (2016)

Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models
por: Davis, S. Lindsey, et al.
Publicado: (2015)

Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer
por: Klauck, Peter J., et al.
Publicado: (2018)

Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models
por: Capasso, Anna, et al.
Publicado: (2018)

From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development
por: Lieu, Christopher H., et al.
Publicado: (2013)

ClustENMD: efficient sampling of biomolecular conformational space at atomic resolution
por: Kaynak, Burak T, et al.
Publicado: (2021)

Systems biology approaches for advancing the discovery of effective drug combinations
por: Ryall, Karen A, et al.
Publicado: (2015)

ATM and MET kinases are synthetic lethal with non-genotoxic activation of p53
por: Sullivan, Kelly D., et al.
Publicado: (2012)

Dual Pharmacological Targeting of the MAP Kinase and PI3K/mTOR Pathway in Preclinical Models of Colorectal Cancer
por: Pitts, Todd M., et al.
Publicado: (2014)

Secteur 40 LEAR (Dessin no. E00-2076-0)
por: Bourquin, P
Publicado: (1988)

Proposal for the Tilecal submodule surface protection with DISKOR V2076-7
por: Valkár, S, et al.
Publicado: (1998)

Genome Sequence of the Halophilic Bacterium Kangiella spongicola ATCC BAA-2076(T)
por: Underriner, Aria, et al.
Publicado: (2018)

RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer
por: Tentler, John J., et al.
Publicado: (2020)

Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts
por: Lieu, Christopher H., et al.
Publicado: (2015)

Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer
por: Pitts, Todd M., et al.
Publicado: (2020)

Fracture patterns and causes in the craniofacial region: an 8-year review of 2076 patients
por: Jin, Ki-Su, et al.
Publicado: (2018)

PB2076: PEDIATRIC-TYPE FOLLICULAR LYMPHOMA - A NEW PARADIGM IN DIAGNOSIS?
por: Fonseca, L., et al.
Publicado: (2022)

A Phase I Dose‐Escalation Study of Linsitinib (OSI‐906), a Small‐Molecule Dual Insulin‐Like Growth Factor‐1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer
por: Davis, S. Lindsey, et al.
Publicado: (2018)

2076. Intestinal colonization with multidrug-resistant organisms, horizontal transmission and risk for bloodstream infection
por: Karakosta, Polyxeni, et al.
Publicado: (2023)

WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma
por: Hartman, Sarah J., et al.
Publicado: (2021)

ENMD-1068 inhibits liver fibrosis through attenuation of TGF-β1/Smad2/3 signaling in mice
por: Sun, Quan, et al.
Publicado: (2017)

Immunotherapy – 2076. A controlled study of delta inulin-adjuvanted honey bee venom immunotherapy
por: Heddle, Robert, et al.
Publicado: (2013)

2076. Expanded Antibiotic Menu Demonstration for Novel Rapid Phenotypic Antimicrobial Susceptibility Testing Platform
por: Stern, Eric, et al.
Publicado: (2018)

PB2076: GUIZHI FULING CAPSULE REGULATES AUTOPHAGY TO INTERFERE WITH BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY
por: Fu, Jiaqi, et al.
Publicado: (2023)

Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models
por: Pitts, Todd M., et al.
Publicado: (2013)

PReS-FINAL-2076: Single centre experience of biologics in clinical practice of systemic juvenile idiopatic arthritis
por: Kaleda, MI, et al.
Publicado: (2013)

Author Correction: ENMD-1068 inhibits liver fibrosis through attenuation of TGF-β1/Smad2/3 signaling in mice
por: Sun, Quan, et al.
Publicado: (2019)

Prognostic Exploration of All-Cause Death in Gingival Squamous Cell Carcinoma: A Retrospective Analysis of 2076 Patients
por: Zheng, Shuai, et al.
Publicado: (2021)

The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p
por: Towers, Christina G., et al.
Publicado: (2015)

E-Health & Innovation to Overcome Barriers in Neuromuscular Diseases. Report from the 1st eNMD Congress: Nice, France, March 22-23, 2019
por: Pini, Jonathan, et al.
Publicado: (2021)

2076. Comparison of Diagnosis and Prescribing Practices between Virtual Visits and Office Visits for Sinusitis within a Primary Care Network
por: Johnson, Kristen, et al.
Publicado: (2019)

The optical aurora
por: Omholt, A
Publicado: (1971)

ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo
por: Moser, Christian, et al.
Publicado: (2008)

Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model
por: Scott, Aaron J., et al.
Publicado: (2017)

Aurora /
por: López Colomé, Pura, 1952-
Publicado: (1994)

Aurora
por: Böhme, Jacob
Publicado: (1979)

Cannot write session to /tmp/vufind_sessions/sess_bpq5s24v070vm4gnd5ndu6nmnv